Alan Cross is the Chief Scientific Officer at Psy Therapeutics and chair of its scientific advisory board. At Psy Therapeutics, Dr. Cross has worked with a team of scientific experts to build an advanced a portfolio of novel projects in the area of neuropsychiatry and neurodegeneration. With over 40 years of research experience within academia and the pharmaceutical industry, Dr. Cross has pursued an understanding the pathophysiology of neuropsychiatric and neurodegenerative disorders and translation into drug discovery and development programs. Dr. Cross has led research teams from the very early phases of target identification through lead optimization, candidate drug selection for clinical study and into human translational neuroscience and clinical development. Dr. Cross was chief scientist and Disease Area Leader in psychiatry at AstraZeneca and a founding member of the AstraZeneca Neuroscience Unit in Cambridge, Massachusetts, which pioneered a virtual model for drug discovery.